Literature DB >> 19884535

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.

Harold J Burstein, Eric P Winer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19884535     DOI： 10.1200/JCO.2009.24.2222

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.

Authors:  John Stagg; Sherene Loi; Upulie Divisekera; Shin Foong Ngiow; Helene Duret; Hideo Yagita; Michele W Teng; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

2.  Association of HER2 Overexpression and Prognosis in Small (T1N0) Primary Breast Cancers.

Authors:  Joachim Rom; Claudia Schumacher; Oleg Gluz; Josef Höfler; Sebastian Eidt; Christoph Domschke; Frederik Marmé; Ulrike Nitz; Christof Sohn; Andreas Schneeweiss
Journal:  Breast Care (Basel)       Date:  2013-06       Impact factor: 2.860

3.  Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

Authors:  Ciara C O'Sullivan; Ian Bradbury; Christine Campbell; Marc Spielmann; Edith A Perez; Heikki Joensuu; Joseph P Costantino; Suzette Delaloge; Priya Rastogi; Dimitrios Zardavas; Karla V Ballman; Eileen Holmes; Evandro de Azambuja; Martine Piccart-Gebhart; Jo Anne Zujewski; Richard D Gelber
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

4.  Behaviour of breast cancer molecular subtypes through tumour progression.

Authors:  Carlos A Castaneda; Eva Andrés; Carmen Barcena; Henry L Gómez; Hernán Cortés-Funés; Eva Ciruelos
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

5.  Morphological and biomolecular characteristics of subcentimetric invasive breast carcinomas in Sicily: A multicentre retrospective study in relation to trastuzumab treatment.

Authors:  A Ieni; G Giuffrè; S Lanzafame; G Nuciforo; M Curduman; L Villari; E Roz; G Certo; D Cabibi; E Salomone; A Labate; D Messina; V Franco; V Adamo; G Tuccari
Journal:  Oncol Lett       Date:  2011-09-20       Impact factor: 2.967

Review 6.  Targeted therapeutic options and future perspectives for HER2-positive breast cancer.

Authors:  Jiani Wang; Binghe Xu
Journal:  Signal Transduct Target Ther       Date:  2019-09-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.